Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Moodys
Healthtrust
Boehringer Ingelheim
McKinsey
Daiichi Sankyo
Accenture
Fuji
US Department of Justice
Chinese Patent Office

Generated: December 11, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,518,421

« Back to Dashboard

Which drugs does patent 8,518,421 protect, and when does it expire?


Patent 8,518,421 protects ABILIFY and is included in one NDA. There have been three Paragraph IV challenges on Abilify.

Protection for ABILIFY has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

Summary for Patent: 8,518,421

Title:Flashmelt oral dosage formulation
Abstract: There is provided granules for the production of flash-melt pharmaceutical oral dosage forms. In addition to one or more medicaments, the granules are composed of an excipient combination consisting of a superdisintegrant, a dispersing agent, a distributing agent, and a binder and may also include other conventional ingredients such as sweetening and flavoring agents. The subject granules are advantageous in that they are stable and can be prepared without the aid of solvents and without the need for special environments or handling. Dosage forms, especially tablets, prepared therefrom on conventional equipment disintegrate in the mouth in under about twenty five seconds.
Inventor(s): Kothari; Sanjeev H. (Princeton, NJ), Desai; Divyakant S. (West Windsor, NJ)
Assignee: Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:13/108,193
Patent Claim Types:
see list of patent claims
Composition; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
OtsukaABILIFYaripiprazoleTABLET, ORALLY DISINTEGRATING;ORAL021729-002Jun 7, 2006DISCNNoNo► Subscribe► Subscribe► SubscribeY
OtsukaABILIFYaripiprazoleTABLET, ORALLY DISINTEGRATING;ORAL021729-003Jun 7, 2006DISCNNoNo► Subscribe► Subscribe► SubscribeY
OtsukaABILIFYaripiprazoleTABLET, ORALLY DISINTEGRATING;ORAL021729-004Jun 7, 2006DISCNYesNo► Subscribe► Subscribe► SubscribeY
OtsukaABILIFYaripiprazoleTABLET, ORALLY DISINTEGRATING;ORAL021729-005Jun 7, 2006DISCNYesNo► Subscribe► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Teva
Moodys
US Army
Fuji
Baxter
Julphar
Harvard Business School
US Department of Justice
Chinese Patent Office
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot